Date: 2014-08-11
Type of information: Development agreement
Compound: placental cell population PSC-100
Company: Human Longevity (USA - CA) Celgene Cellular Therapeutics (USA - CA)
Therapeutic area:
Type agreement:
Action mechanism:
Disease: sarcopenia
Details: * On August 11, 2014, Human Longevity, a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, announced it has signed an agreement with Celgene Cellular Therapeutics (CCT) to license, develop, and co-promote Celgene\'s proprietary placental cell population, PSC-100. Human Longevity has the option to explore a variety of applications for this unique cell population, including for sarcopenia, a condition associated with aging characterized by degenerative loss of skeletal muscle mass, quality, and strength. Celgene has also made an equity investment in Human Longevity. Human Longevity will use its vast expertise and technology to sequence and characterize PSC-100 at the molecular level to complement data Celgene has gleaned from PSC-100 in Phase 1 human studies. HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy (J. Craig Venter, Ph.D., HLI CEO and Co-Founder). Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world\'s most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings.
Financial terms:
Latest news:
